Home
Peptides

 

SAE Media Group are presenting their inaugural conference on Peptide Therapeutics.

As the global Peptide Therapeutics market is expected to reach over $25 billion by 2018, the market is strongly trying to develop new peptide therapeutics and better formulations to enhance drug delivery. Even though peptides is a relatively niche market – it has a fast growth rate with many products in development.

The conference will enable you to assess biophysical characterisation such as solubility and stability in addition to reviewing analytcial techniques for monitoring peptides. Focus is on optimisation, extending the half-life and assessing alternative technologies in peptide analysis. 

Attention to detail is key in the formulation and delivery of peptides and SAE Media Group pride themselves in delivering a thorough conference with this focus in mind.  Presentations will include the assessment of new formulations and routes of administration i.e. oral, as well as reviewing compliance and efficacy challenges.

FEATURED SPEAKERS

David  Price

David Price

Senior Director , Pfizer
Dieter Deforce

Dieter Deforce

Professor at the University of Gent, Belgium, Member of the Scientific Advice Working Party of the EMA, Gent University
Dinesh Patel

Dinesh Patel

President and CEO , Protagonist Therapeutics
Doug Treco

Doug Treco

President and CEO, Ra Pharmaceuticals
Mark Currie

Mark Currie

President of R&D, Chief Scientific Officer, Ironwood Pharmaceuticals Inc
Ved Srivastava

Ved Srivastava

Head, Peptide Chemistry, GSK
Yvonne Angell

Yvonne Angell

Director of Peptide and Protein Chemistry, Ipsen Inc.

Annette Friebe

Head of Late Discovery , Nexigen
Annette Friebe

Christian Luber

Senior Scientist , Novo Nordisk Pharmaceuticals Incorporated
Christian  Luber

Christophe Bonny

CSO, Bicycle Therapeutics
Christophe Bonny

David Price

Senior Director , Pfizer
David  Price

Dieter Deforce

Professor at the University of Gent, Belgium, Member of the Scientific Advice Working Party of the EMA, Gent University
Dieter Deforce

Dinesh Patel

President and CEO , Protagonist Therapeutics
Dinesh Patel

Doug Treco

President and CEO, Ra Pharmaceuticals
Doug Treco

Fredrik Tiberg

CEO & President , Camurus
Fredrik Tiberg

Gregory T. Bourne

Research Fellow , Protagonist Therapeutics
Gregory  T. Bourne

Ian Lewis

Investigator III, Peptide Discovery Group, Exploratory Medicinal Chemistry Unit, Novartis Institutes of Biomedical Research
Ian Lewis

Joel Richard

Senior Vice President, Peptides, IPSEN S.A.S
Joel Richard

Mark Currie

President of R&D, Chief Scientific Officer, Ironwood Pharmaceuticals Inc
Mark Currie

Paul Watt

CSO, Phylogica Ltd
Paul  Watt

Ved Srivastava

Head, Peptide Chemistry, GSK
Ved Srivastava

Vincenzo Abbate

Research Associate, Kings College London
Vincenzo Abbate

Yvonne Angell

Director of Peptide and Protein Chemistry, Ipsen Inc.
Yvonne Angell

Conference agenda

clock

8:30

Registration & Coffee

clock

9:00

Chairs Opening Remarks

Yvonne Angell

Yvonne Angell, Director of Peptide and Protein Chemistry, Ipsen Inc.

clock

9:10

Case Study: Development of cell-permeable therapeutic peptides targeting Wnt signalling in cancer

Annette Friebe

Annette Friebe, Head of Late Discovery , Nexigen

  • Indentification of functional peptides utilising a cellular yeast screening platform
  • Development of cell-permeable peptides with anti-tumour activity in vitro and in vivo
  • Pharmacology of the lead candidate
  • clock

    9:50

    Oral Bioavailability of Peptides

    David  Price

    David Price , Senior Director , Pfizer

  • Strategic way to bring new products to market that are more efficient and have hgher efficacy
  • Linking PK and bio-distribution of peptide therapeutics with thier pharmacological activity
  • Future directions
  • clock

    10:30

    Morning Coffee

    clock

    11:00

    AQUA for peptide quantification and regulatory aspects of peptide drugs

    Dieter Deforce

    Dieter Deforce, Professor at the University of Gent, Belgium, Member of the Scientific Advice Working Party of the EMA, Gent University

  • The use of isotopically labelled synthetic peptides for the absolute quantitation of a specific peptide in a complex mixture using LC-MS/MS 
  • Some regulatory aspects will be discussed such as: generic/biosimilar, synthetic versus biologic, transdermal, oral, inhalation versus injection
  • clock

    11:40

    Strategies to enhance the development of novel peptide drugs

    Yvonne Angell

    Yvonne Angell, Director of Peptide and Protein Chemistry, Ipsen Inc.

    clock

    12:20

    Networking Lunch

    clock

    13:30

    Reviewing peptide engineering for the optimisation of drug like properties

    Ved Srivastava

    Ved Srivastava, Head, Peptide Chemistry, GSK

    Peptide therapy has become a key strategy of innovative drug development. One of the potential barriers to the use of the native peptides in the clinic is their short half-lives.The presentation will emphasize:

  • Attributes necessary for a commercially successful metabolic peptide
  • Strategies and tactics for the design and development of peptidase-resistant peptide analogs
  • Strategies for half-life extension to increase the duration of effect including formulation tactics for patient friendly peptide delivery
  • clock

    14:10

    SOM230: A new therapeutic modality for Cushing’s disease

    Ian Lewis

    Ian Lewis, Investigator III, Peptide Discovery Group, Exploratory Medicinal Chemistry Unit, Novartis Institutes of Biomedical Research

    clock

    14:50

    Afternoon Tea

    clock

    15:20

    Novel Hepcidin Agonists

    Gregory  T. Bourne

    Gregory T. Bourne, Research Fellow , Protagonist Therapeutics

  • Hepcidin is a natural peptide hormone that regulates iron homeostasis.   Hepcidin deficiency is associated with iron overload disorders such as beta-thalassemia and juvenile hemochromatosis
  •  Hepcidin is structurally complex (25-mer with 4-disulfide-cross linked beta-hairpin), difficult to synthesize, and prone to aggregation. A hepcidin agonist with suitable drug-like properties is highly desired.
  • Protagonist has utilized its proprietary VectrixTM technology platform and ‘scaffold hoping’ to identify novel hepcidin agonists with equivalent in vivo potency to hepcidin and superior physiochemical properties
  • clock

    16:00

    Extending the Half-Life of Peptides

    Yvonne Angell

    Yvonne Angell, Director of Peptide and Protein Chemistry, Ipsen Inc.

    clock

    16:40

    Direct Selection of Drug-Like Macrocyclic Peptides from In Vitro Display Libraries Built with Unnatural Amino Acids

    Doug Treco

    Doug Treco, President and CEO, Ra Pharmaceuticals

  • High affinity macrocycles are isolated by affinity to targets of interest                                                                                                                                                                                                   
  • Macrocyclic peptides can adopt conformations that promote extensive intramolecular hydrogen bonding
  • Cell permeability is apparent with certain molecules
  • clock

    17:20

    Chairs Closing Remarks and Close of Day One

    clock

    8:30

    Registration & Coffee

    clock

    9:00

    Chairman's Opening Remarks

    Joel Richard

    Joel Richard, Senior Vice President, Peptides, IPSEN S.A.S

    clock

    9:10

    Peptide Delivery: Where Do We Stand and What Does the Furute Hold?

    Joel Richard

    Joel Richard, Senior Vice President, Peptides, IPSEN S.A.S

    clock

    9:50

    The 'Endosome Escape Trap’: a new tool to discover peptides which efficiently deliver cargoes to the cytoplasm

    Paul  Watt

    Paul Watt, CSO, Phylogica Ltd

  • Phylomers are structure-rich peptides derived from biodiverse protein fragments
  • The 'Endosome Escape Trap' allows capture of rare cell penetrating peptides which have escaped from the endosome to delivery their cargoes to the cytoplasm
  • Novel functional assays were devised quantitate the extent of delivery of protein cargoes to the cytoplasm
  • Phylogica has discovered more efficient cell penetrating peptides with this approach known as FPP’s (Functional Penetrating Peptides)
  • Ranking of peptides using such functional assays shows that some FPP’s are more efficient than conventional CPP’s
  • clock

    10:30

    Morning Coffee

    clock

    11:00

    Responsive delivery systems for extended release of peptides and proteins

    Fredrik Tiberg

    Fredrik Tiberg , CEO & President , Camurus

  • Strategies for solubilisation and stability enhancement
  • Tuning release rates
  • Manufacturing and device selection
  • clock

    11:40

    Oral Peptide Drugs

    Dinesh Patel

    Dinesh Patel, President and CEO , Protagonist Therapeutics

  • Oral peptide drugs can offer excellent advantages to patients, physicians, and payers versus those targets and diseases wherein ‘injectable antibodies’ is the only available targeted therapy option.
  • Two complimentary approaches will be discussed – engineering core oral stability in peptide scaffolds vs. using specialized formulation/delivery approaches to protect and off-load the drug to the desired site of action.
  • Protagonist will disclose its progress towards ‘oral peptides for IBD’ on a clinically validated target.
  • clock

    12:20

    Networking Lunch

    clock

    13:30

    Bi-Cyclic Peptides to Target Protein-Protein Interactions

    Christophe Bonny

    Christophe Bonny, CSO, Bicycle Therapeutics

    clock

    14:10

    Targeting Mitochondria with Cationic Amphipathic Short Peptides

    Vincenzo Abbate

    Vincenzo Abbate, Research Associate, Kings College London

  • Mitochondria play an important role in oxidative stress, acting as the main source of Reactive Oxygen Species (ROS) generation
  • A novel class of water-soluble tetrapeptides (“SS peptides”) was recently reported, with the view to protect cells against ROS-mediated oxidative stress. These peptides consist of alternating aromatic and basic residues and are able to selectively target the inner membrane of mitochondria; furthermore, such small-peptide antioxidants are believed to penetrate cells in an energy-independent and non-saturable manner without a need for peptide transporter.
  • We have designed a series of fluorescently-labeled short peptides and have evaluated their ability to co-localize with mitochondria. The effect of different dyes on their biological behaviour was investigated. It was found that the size of the fluorescent probe strongly affected the ability of the compound to efficiently co-localize with mitochondria.
  •  Dansylated peptides were selected as models for the subsequent incorporation of iron-chelating moieties into the backbone sequence to provide a novel class of mitochondria-targeted iron chelators.
  • clock

    14:50

    Afternoon Tea

    clock

    15:20

    The Use of Guanylate Cyclase-C Agonists for the Treatment of Gastrointestional Disorders

    Mark Currie

    Mark Currie, President of R&D, Chief Scientific Officer, Ironwood Pharmaceuticals Inc

  • Guanylate Cyclase-C (GCC) is a receptor expressed on the intestinal epithelial lumen surface

  • Stimulation of this receptor stimulates a visceral analgesia and fluid secretion

  • Linaclotide, a GCC agonist, is approved in the US and EU for the treatment of IBS-C

     

  • clock

    16:00

    Manufacturability - understanding the criteria to form a peptide sequence

  • What challenges are being faced for manufacturing products? 
  • Understanding the characterisation of peptides to understand thier risk profile, e.g solubility
  • Assessing how the product could behave in large scale manufacturing
  • Joel Richard

    Joel Richard, Senior Vice President, Peptides, IPSEN S.A.S

    David  Price

    David Price , Senior Director , Pfizer

    Dinesh Patel

    Dinesh Patel, President and CEO , Protagonist Therapeutics

    clock

    16:20

    Chairman’s Closing Remarks and Close of Day Two


    Head of Late Discovery
    Nexigen
    Senior Scientist
    Novo Nordisk Pharmaceuticals Incorporated
    CSO
    Bicycle Therapeutics
    Senior Director
    Pfizer
    Professor at the University of Gent, Belgium, Member of the Scientific Advice Working Party of the EMA
    Gent University
    President and CEO
    Protagonist Therapeutics
    President and CEO
    Ra Pharmaceuticals
    CEO & President
    Camurus
    Research Fellow
    Protagonist Therapeutics
    Investigator III, Peptide Discovery Group, Exploratory Medicinal Chemistry Unit
    Novartis Institutes of Biomedical Research
    Senior Vice President, Peptides
    IPSEN S.A.S
    President of R&D, Chief Scientific Officer
    Ironwood Pharmaceuticals Inc
    CSO
    Phylogica Ltd
    Head, Peptide Chemistry
    GSK
    Research Associate
    Kings College London
    Director of Peptide and Protein Chemistry
    Ipsen Inc.

    Speaker Q&A with Joel Richard, Senior Vice President, Peptides, IPSEN S.A.S

    Download

    Marriott Regents Park

    128 King Henry's Road
    London NW3 3ST
    United Kingdom

    Marriott Regents Park

    This 4 star north London hotel in zone 2 is the perfect destination for the astute business traveler as well as the leisure guest that knows how convenient north London hotels are, as a base from which to explore the city .Bond Street is just 3 stops from Swiss Cottage underground station on the Jubilee Line, so you can be shopping, exploring the sights and taking in one of London’s world-renowned West End shows in less than 15 minutes when you stay at this hotel near central London. At the same time, the hive of activity that is Camden Town, the chic shops, cafes and restaurants of Primrose Hill and ZSL’s London Zoo in Regents Park are all just a short walk from this hotel in north London.

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download

    Title


    Description

    Download

    Title


    Description


    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SAE Media Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@saemediagroup.com

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    Group Booking

    Please complete the below form and a member of SAE Media Group’s booking team will be in contact within 24 hours

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SAE Media Group

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SAE Media Group , Ground Floor, India House, 45 Curlew Street, London, SE1 2ND, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smgconferences.com Email: events@saemediagroup.com
    Registered in England - SMi Group Ltd trading as SAE Media Group




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.

    Thank you for visiting our event

    If you would like to receive further information about our events, please fill out the information below.

    By ticking above you are consenting to receive information by email from SAE Media Group.
    Full details of our privacy policy can be found here https://www.smgconferences.com/privacy-legals/privacy-policy/.
    Should you wish to update your contact preferences at any time you can contact us at data.privacy@smgconferences.com.
    Should you wish to be removed from any future mailing lists please click on the following link http://www.smgconferences.com/opt-out

    Fill in your details to download the brochure

    By submitting this form you agree to our privacy policy and consent to receiving communications, you may opt out at any time.